Penumbra shares are trading higher after the company announced it completed the enrollment in its THUNDER clinical study for patients with acute ischemic stroke. Also, Truist Securities maintained a Buy rating on the stock and raised its price target from $200 to $235.
Portfolio Pulse from Benzinga Newsdesk
Penumbra shares rose following the completion of enrollment in its THUNDER clinical study for acute ischemic stroke. Truist Securities maintained a Buy rating and increased the price target from $200 to $235.
October 14, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Penumbra's stock is trading higher due to the completion of enrollment in its THUNDER clinical study and a positive analyst rating from Truist Securities, which raised the price target to $235.
The completion of the THUNDER study enrollment is a significant milestone for Penumbra, potentially leading to positive clinical outcomes and future revenue. Additionally, Truist Securities' increased price target and maintained Buy rating provide a strong endorsement, likely boosting investor confidence and driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100